(Q50310405)

2 March 2018

title

Design and subject characteristics in the federally-funded citalopram trial in children with pervasive developmental disorders. (English)

1 reference

2 March 2018

author

Lawrence Scahill

1

1 reference

2 March 2018

Lisa M Sullivan

10

1 reference

2 March 2018

Evdokia Anagnostou

11

object named as

Evdokia Anagnostou

1 reference

2 March 2018

5

Eric Hollander

1 reference

2 March 2018

author name string

James T McCracken

2

1 reference

2 March 2018

Karen Bearss

3

1 reference

2 March 2018

Fay Robinson

4

1 reference

2 March 2018

Bryan King

6

1 reference

2 March 2018

Joel Bregman

7

1 reference

2 March 2018

Lin Sikich

8

1 reference

2 March 2018

Kimberly Dukes

9

1 reference

2 March 2018

Craig Donnelly

12

1 reference

2 March 2018

Young-Shin Kim

13

1 reference

2 March 2018

Louise Ritz

14

1 reference

2 March 2018

Deborah Hirtz

15

1 reference

2 March 2018

Ann Wagner

16

1 reference

2 March 2018

language of work or name

English

0 references

publication date

1 March 2012

1 reference

2 March 2018

Journal of Autism and Developmental Disorders

published in

1 reference

2 March 2018

volume

42

1 reference

2 March 2018

issue

3

1 reference

2 March 2018

page(s)

432-440

1 reference

2 March 2018

Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

21 January 2018

Bayesian clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

The multiphase optimization strategy (MOST) and the sequential multiple assignment randomized trial (SMART): new methods for more potent eHealth interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Caution regarding the use of pilot studies to guide power calculations for study proposals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Prevalence of chronic gastrointestinal symptoms in children with autism and autistic spectrum disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Gastrointestinal symptoms in a sample of children with pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Trial design challenges when combining medication and parent training in children with pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Risperidone in children with autism and serious behavioral problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10803-011-1251-8

Novel and emerging treatments for autism spectrum disorders: a systematic review

21 January 2018

1 reference

12 December 2020

Epidemiology of autistic disorder and other pervasive developmental disorders

1 reference

12 December 2020

Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, 14 sites, United States, 2002.

1 reference

12 December 2020

Subject selection and characterization in clinical trials in children with autism.

1 reference

12 December 2020

Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity

1 reference

12 December 2020

10.1007/S10803-011-1251-8

Identifiers

DOI

1 reference

2 March 2018

1 reference

2 March 2018